Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H C van Zaanen

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Cancer|April 1, 1992
Thiamine deficiency in hematologic malignant tumorsH C van Zaanen, J van der Lelie
Annals of Hematology|May 1, 1993
Interleukin-6, a new target for therapy in multiple myeloma?M H van Oers, H C van Zaanen, H M Lokhorst
Nederlands Tijdschrift Voor Geneeskunde|March 23, 1999
[Pleural amyloidosis as a cause of excessive pleural effusions]J G Aerts, K Y Tan, M Veerhoek, et al.
Nederlands Tijdschrift Voor Geneeskunde|November 22, 2000
[Renal insufficiency due to light chain multiple myeloma]H C van Zaanen, P P Diderich, J G Pegels, et al.
Cancer|November 15, 1994
Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicityH C van Zaanen, H van der Lelie, J G Timmer, et al.
Leukemia & Lymphoma|January 28, 1999
Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130H C Van Zaanen, H M Lokhorst, L A Aarden, et al.
British Journal of Haematology|September 1, 1995
A simple and sensitive method for determining plasma cell isotype and monoclonality in bone marrow using flowcytometryH C van Zaanen, R J Vet, C M de Jong, et al.
British Journal of Haematology|August 29, 1998
Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating studyH C van Zaanen, H M Lokhorst, L A Aarden, et al.
The Journal of Clinical Investigation|September 15, 1996
Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loopH C van Zaanen, R P Koopmans, L A Aarden, et al.
Metabolism: Clinical and Experimental|November 15, 1997
Modulation of chronic excessive interleukin-6 production in multiple myeloma does not affect thyroid hormone concentrationsH C van Zaanen, J A Romijn, H P Sauerwein, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cancer|April 1, 1992
Thiamine deficiency in hematologic malignant tumorsH C van Zaanen, J van der Lelie
Annals of Hematology|May 1, 1993
Interleukin-6, a new target for therapy in multiple myeloma?M H van Oers, H C van Zaanen, H M Lokhorst
Nederlands Tijdschrift Voor Geneeskunde|March 23, 1999
[Pleural amyloidosis as a cause of excessive pleural effusions]J G Aerts, K Y Tan, M Veerhoek, et al.
Nederlands Tijdschrift Voor Geneeskunde|November 22, 2000
[Renal insufficiency due to light chain multiple myeloma]H C van Zaanen, P P Diderich, J G Pegels, et al.
Cancer|November 15, 1994
Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicityH C van Zaanen, H van der Lelie, J G Timmer, et al.
Leukemia & Lymphoma|January 28, 1999
Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130H C Van Zaanen, H M Lokhorst, L A Aarden, et al.
British Journal of Haematology|September 1, 1995
A simple and sensitive method for determining plasma cell isotype and monoclonality in bone marrow using flowcytometryH C van Zaanen, R J Vet, C M de Jong, et al.
British Journal of Haematology|August 29, 1998
Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating studyH C van Zaanen, H M Lokhorst, L A Aarden, et al.
The Journal of Clinical Investigation|September 15, 1996
Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loopH C van Zaanen, R P Koopmans, L A Aarden, et al.
Metabolism: Clinical and Experimental|November 15, 1997
Modulation of chronic excessive interleukin-6 production in multiple myeloma does not affect thyroid hormone concentrationsH C van Zaanen, J A Romijn, H P Sauerwein, et al.
Pageof 2